FindTrial
Sign In

Study on the Risk Factors and Safe Dose of Anhydrous Ethanol Treatment for Pulmonary Hypertension Induced by Arteriovenous Malformation

Study on the Risk Factors and Safe Dose of Anhydrous Ethanol Treatment for Pulmonary Hypertension Induced by Arteriovenous Malformation

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500103248
Enrollment
Unknown
Registered
2025-05-27
Start date
2025-06-02
Completion date
Unknown
Last updated
2025-06-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Arteriovenous malformation

Interventions

case group:None
control group:None

Sponsors

Capital Children's Medical Center Affiliated to Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
0.5 Years to 18 Years

Inclusion criteria

Inclusion criteria: 1. Sign the informed consent form for the research; 2. Age: 6 months to 18 years old; 3. Diagnosed with vascular malformation based on medical history and imaging examination.

Exclusion criteria

Exclusion criteria: 1. Congenital heart disease; 2. History of PAH; 3. Allergy to contrast agents and ethanol; 4. Heart, liver, and kidney dysfunction; 5. Residential altitude>2500 meters.

Design outcomes

Primary

MeasureTime frame
Pulmonary artery pressure;Duration of pulmonary arterial hypertension;Usage frequency and dosage of anhydrous ethanol;treatment effect ;—

Secondary

MeasureTime frame
cerebral regional oxygen saturation;EEG bispectral index;—

Countries

China

Contacts

Public ContactSiyuan Xie

Capital Children's Medical Center Affiliated to Capital Medical University

siyuan_xie@163.com+86 187 1009 2782

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026